


## B7/CD28 interaction inhibitor 1

<b>Cat. No.:</b>	HY-102090		
<b>CAS No.:</b>	635324-72-0		
<b>Molecular Formula:</b>	C <sub>21</sub> H <sub>13</sub> F <sub>4</sub> N <sub>5</sub> O		
<b>Molecular Weight:</b>	427.35		
<b>Target:</b>	Others		
<b>Pathway:</b>	Others		
<b>Storage:</b>	Powder	-20°C	3 years
		4°C	2 years
	In solvent	-80°C	6 months
		-20°C	1 month



### SOLVENT & SOLUBILITY

<b>In Vitro</b>	DMSO : 62.5 mg/mL (146.25 mM; Need ultrasonic)				
		Solvent Concentration	Mass 1 mg	5 mg	10 mg
	<b>Preparing Stock Solutions</b>	1 mM	2.3400 mL	11.7000 mL	23.4000 mL
		5 mM	0.4680 mL	2.3400 mL	4.6800 mL
10 mM		0.2340 mL	1.1700 mL	2.3400 mL	
Please refer to the solubility information to select the appropriate solvent.					
<b>In Vivo</b>	1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline Solubility: 2.08 mg/mL (4.87 mM); Suspended solution; Need ultrasonic				

### BIOLOGICAL ACTIVITY

<b>Description</b>	B7/CD28 interaction inhibitor 1 (compound 6b) is a potent B7.1-CD28 interaction inhibitor with an IC <sub>50</sub> of 50 nM <sup>[1]</sup> .
<b>IC<sub>50</sub> &amp; Target</b>	IC <sub>50</sub> : 50 nM (B7.1-CD28 interaction) <sup>[1]</sup>
<b>In Vitro</b>	<p>Bivalent CTLA4 homodimers bridge bivalent B7.1 homodimers to form an unusually stable signaling complex. Blocking B7/CD28 interactions with monoclonal antibodies or soluble receptors results in immunosuppression and enhanced allograft survival, while B7/CTLA-4 blockade results in enhanced antitumor immune responses. The interaction of co-stimulatory molecules on T cells with B7 molecules on antigen presenting cells plays an important role in the activation of naive T cells. Consequently, agents that disrupt these interactions should have applications in treatment of transplant rejection as well as autoimmune diseases<sup>[1]</sup>.</p> <p>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p>

---

## REFERENCES

---

[1]. Green NJ, et al. Structure-activity studies of a series of dipyrzolo[3,4-b:3',4'-d]pyridin-3-ones binding to the immune regulatory protein B7.1. Bioorg Med Chem. 2003 Jul 3;11(13):2991-3013.

---

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: [tech@MedChemExpress.com](mailto:tech@MedChemExpress.com)

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA